Molecular Cancer Therapeutics: 17 (2)

Highlights

Highlights

Highlights of This Issue

Mol Cancer Ther February 1 2018 17 (2) 329-329;

MCT Focus: Developmental Therapeutics in Radiation Oncology

MCT Focus: Developmental Therapeutics in Radiation Oncology

Refining Radiation for the Next Century

John S. Lazo

Mol Cancer Ther February 1 2018 17 (2) 332-335; DOI:10.1158/1535-7163.MCT-17-1244
MCT Focus: Developmental Therapeutics in Radiation Oncology

Lack of Constitutively Active DNA Repair Sensitizes Glioblastomas to Akt Inhibition and Induces Synthetic Lethality with Radiation Treatment in a p53-Dependent Manner

Kamalakannan Palanichamy, Disha Patel, John R. Jacob, Kevin T. Litzenberg, Nicolaus Gordon, Kirstin Acus, Shin-ei Noda and Arnab Chakravarti

Mol Cancer Ther February 1 2018 17 (2) 336-346; DOI:10.1158/1535-7163.MCT-17-0429
MCT Focus: Developmental Therapeutics in Radiation Oncology

Identification of MEK162 as a Radiosensitizer for the Treatment of Glioblastoma

Ravi S. Narayan, Ana Gasol, Paul L.G. Slangen, Fleur M.G. Cornelissen, Tonny Lagerweij, Hou Y.Y.E. Veldman, Rogier Dik, Jaap van den Berg, Ben J. Slotman, Tom Würdinger, Daphne A. Haas-Kogan, Lukas J.A. Stalpers, Brigitta G. Baumert, Bart A. Westerman, Jan Theys and Peter Sminia

Mol Cancer Ther February 1 2018 17 (2) 347-354; DOI:10.1158/1535-7163.MCT-17-0480
MCT Focus: Developmental Therapeutics in Radiation Oncology

Exploiting Radiation-Induced Signaling to Increase the Susceptibility of Resistant Cancer Cells to Targeted Drugs: AKT and mTOR Inhibitors as an Example

Iris Eke, Adeola Y. Makinde, Molykutty J. Aryankalayil, Veit Sandfort, Sanjeewani T. Palayoor, Barbara H. Rath, Lance Liotta, Mariaelena Pierobon, Emanuel F. Petricoin, Matthew F. Brown, Jayne M. Stommel, Mansoor M. Ahmed and C. Norman Coleman

Mol Cancer Ther February 1 2018 17 (2) 355-367; DOI:10.1158/1535-7163.MCT-17-0262
MCT Focus: Developmental Therapeutics in Radiation Oncology | AuthorChoice

The Neddylation Inhibitor Pevonedistat (MLN4924) Suppresses and Radiosensitizes Head and Neck Squamous Carcinoma Cells and Tumors

Vanessa Vanderdys, Amir Allak, Fadila Guessous, Mouadh Benamar, Paul W. Read, Mark J. Jameson and Tarek Abbas

Mol Cancer Ther February 1 2018 17 (2) 368-380; DOI:10.1158/1535-7163.MCT-17-0083
MCT Focus: Developmental Therapeutics in Radiation Oncology

Radiosensitization In Vivo by Histone Deacetylase Inhibition with No Increase in Early Normal Tissue Radiation Toxicity

Blaz Groselj, Jia-Ling Ruan, Helen Scott, Jessica Gorrill, Judith Nicholson, Jacqueline Kelly, Selvakumar Anbalagan, James Thompson, Michael R.L. Stratford, Sarah J. Jevons, Ester M. Hammond, Cheryl L. Scudamore, Martin Kerr and Anne E. Kiltie

Mol Cancer Ther February 1 2018 17 (2) 381-392; DOI:10.1158/1535-7163.MCT-17-0011
MCT Focus: Developmental Therapeutics in Radiation Oncology

Arginine Deprivation Therapy: Putative Strategy to Eradicate Glioblastoma Cells by Radiosensitization

C. Noreen Hinrichs, Mirjam Ingargiola, Theresa Käubler, Steffen Löck, Achim Temme, Alvaro Köhn-Luque, Andreas Deutsch, Olena Vovk, Oleh Stasyk and Leoni A. Kunz-Schughart

Mol Cancer Ther February 1 2018 17 (2) 393-406; DOI:10.1158/1535-7163.MCT-16-0807
MCT Focus: Developmental Therapeutics in Radiation Oncology

HMG-CoA Reductase Inhibition Delays DNA Repair and Promotes Senescence After Tumor Irradiation

Elena V. Efimova, Natalia Ricco, Edwardine Labay, Helena J. Mauceri, Amy C. Flor, Aishwarya Ramamurthy, Harold G. Sutton, Ralph R. Weichselbaum and Stephen J. Kron

Mol Cancer Ther February 1 2018 17 (2) 407-418; DOI:10.1158/1535-7163.MCT-17-0288
MCT Focus: Developmental Therapeutics in Radiation Oncology

A CRISPR/Cas9–Based Screening for Non-Homologous End Joining Inhibitors Reveals Ouabain and Penfluridol as Radiosensitizers

Jie Du, Jun Shang, Fei Chen, Yushuo Zhang, Narui Yin, Ting Xie, Haowen Zhang, Jiahua Yu and Fenju Liu

Mol Cancer Ther February 1 2018 17 (2) 419-431; DOI:10.1158/1535-7163.MCT-17-0090
MCT Focus: Developmental Therapeutics in Radiation Oncology

A Chemical Modulator of p53 Transactivation that Acts as a Radioprotective Agonist

Akinori Morita, Ippei Takahashi, Megumi Sasatani, Shin Aoki, Bing Wang, Shinya Ariyasu, Kaoru Tanaka, Tetsuji Yamaguchi, Akiko Sawa, Yurie Nishi, Tatsuro Teraoka, Shohei Ujita, Yosuke Kawate, Chihiro Yanagawa, Keiji Tanimoto, Atsushi Enomoto, Mitsuru Nenoi, Kenji Kamiya, Yasushi Nagata, Yoshio Hosoi and Toshiya Inaba

Mol Cancer Ther February 1 2018 17 (2) 432-442; DOI:10.1158/1535-7163.MCT-16-0554

Small Molecule Therapeutics

Small Molecule Therapeutics | AuthorChoice

A Novel YAP1 Inhibitor Targets CSC-Enriched Radiation-Resistant Cells and Exerts Strong Antitumor Activity in Esophageal Adenocarcinoma

Shumei Song, Min Xie, Ailing W. Scott, Jiankang Jin, Lang Ma, Xiaochuan Dong, Heath D. Skinner, Randy L. Johnson, Sheng Ding and Jaffer A. Ajani

Mol Cancer Ther February 1 2018 17 (2) 443-454; DOI:10.1158/1535-7163.MCT-17-0560
Small Molecule Therapeutics

Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3–Positive Acute Myeloid Leukemia

Kristen M. Smith, Patrick C. Fagan, Elena Pomari, Giuseppe Germano, Chiara Frasson, Colin Walsh, Ian Silverman, Paolo Bonvini and Gang Li

Mol Cancer Ther February 1 2018 17 (2) 455-463; DOI:10.1158/1535-7163.MCT-17-0419
Small Molecule Therapeutics

Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer

Yan Huang, Wei Hu, Jie Huang, Fangrong Shen, Yunjie Sun, Cristina Ivan, Sunila Pradeep, Robert Dood, Monika Haemmerle, Dahai Jiang, Lingegowda S. Mangala, Kyunghee Noh, Jean M. Hansen, Heather J. Dalton, Rebecca A. Previs, Archana S. Nagaraja, Michael McGuire, Nicholas B. Jennings, Russell Broaddus, Robert L. Coleman and Anil K. Sood

Mol Cancer Ther February 1 2018 17 (2) 464-473; DOI:10.1158/1535-7163.MCT-17-0006
Small Molecule Therapeutics

COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin

Fuli Wang, Hongyong Zhang, Ai-Hong Ma, Weimin Yu, Maike Zimmermann, Jun Yang, Sung Hee Hwang, Daniel Zhu, Tzu-yin Lin, Michael Malfatti, Kenneth W. Turteltaub, Paul T. Henderson, Susan Airhart, Bruce D. Hammock, Jianlin Yuan, Ralph W. de Vere White and Chong-Xian Pan

Mol Cancer Ther February 1 2018 17 (2) 474-483; DOI:10.1158/1535-7163.MCT-16-0818
Small Molecule Therapeutics

Inhibition of O-GlcNAcase Sensitizes Apoptosis and Reverses Bortezomib Resistance in Mantle Cell Lymphoma through Modification of Truncated Bid

Sudjit Luanpitpong, Nawin Chanthra, Montira Janan, Jirarat Poohadsuan, Parinya Samart, Yaowalak U-Pratya, Yon Rojanasakul and Surapol Issaragrisil

Mol Cancer Ther February 1 2018 17 (2) 484-496; DOI:10.1158/1535-7163.MCT-17-0390
Small Molecule Therapeutics

Inhibition of MDM2 by a Rhein-Derived Compound AQ-101 Suppresses Cancer Development in SCID Mice

Lubing Gu, Hailong Zhang, Tao Liu, Alexander Draganov, Sha Yi, Binghe Wang and Muxiang Zhou

Mol Cancer Ther February 1 2018 17 (2) 497-507; DOI:10.1158/1535-7163.MCT-17-0566
Small Molecule Therapeutics

Mechanism-informed Repurposing of Minocycline Overcomes Resistance to Topoisomerase Inhibition for Peritoneal Carcinomatosis

Huang-Chiao Huang, Joyce Liu, Yan Baglo, Imran Rizvi, Sriram Anbil, Michael Pigula and Tayyaba Hasan

Mol Cancer Ther February 1 2018 17 (2) 508-520; DOI:10.1158/1535-7163.MCT-17-0568

Cancer Biology and Translational Studies

Cancer Biology and Translational Studies

Molecular Basis for Necitumumab Inhibition of EGFR Variants Associated with Acquired Cetuximab Resistance

Atrish Bagchi, Jaafar N. Haidar, Scott W. Eastman, Michal Vieth, Michael Topper, Michelle D. Iacolina, Jason M. Walker, Amelie Forest, Yang Shen, Ruslan D. Novosiadly and Kathryn M. Ferguson

Mol Cancer Ther February 1 2018 17 (2) 521-531; DOI:10.1158/1535-7163.MCT-17-0575
Cancer Biology and Translational Studies

A Role for CXCR4 in Peritoneal and Hematogenous Ovarian Cancer Dissemination

Agnès Figueras, Elisenda Alsina-Sanchís, Álvaro Lahiguera, Manuel Abreu, Laura Muinelo-Romay, Gema Moreno-Bueno, Oriol Casanovas, Mariona Graupera, Xavier Matias-Guiu, August Vidal, Alberto Villanueva and Francesc Viñals

Mol Cancer Ther February 1 2018 17 (2) 532-543; DOI:10.1158/1535-7163.MCT-17-0643

Large Molecule Therapeutics

Large Molecule Therapeutics | AuthorChoice

β-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models

Shanthi Ganesh, Xue Shui, Kevin P. Craig, Martin L. Koser, Girish R. Chopda, Wendy A. Cyr, Chengjung Lai, Henryk Dudek, Weimin Wang, Bob D. Brown and Marc T. Abrams

Mol Cancer Ther February 1 2018 17 (2) 544-553; DOI:10.1158/1535-7163.MCT-17-0605
Large Molecule Therapeutics | AuthorChoice

Characterization of SGN-CD123A, A Potent CD123-Directed Antibody–Drug Conjugate for Acute Myeloid Leukemia

Fu Li, May Kung Sutherland, Changpu Yu, Roland B. Walter, Lori Westendorf, John Valliere-Douglass, Lucy Pan, Ashley Cronkite, Django Sussman, Kerry Klussman, Michelle Ulrich, Martha E. Anderson, Ivan J. Stone, Weiping Zeng, Mechthild Jonas, Timothy S. Lewis, Maitrayee Goswami, Sa A. Wang, Peter D. Senter, Che-Leung Law, Eric J. Feldman and Dennis R. Benjamin

Mol Cancer Ther February 1 2018 17 (2) 554-564; DOI:10.1158/1535-7163.MCT-17-0742
Large Molecule Therapeutics

An Infrared Dye–Conjugated Virus-like Particle for the Treatment of Primary Uveal Melanoma

Rhonda C. Kines, Isabella Varsavsky, Sanghamitra Choudhary, Debaditya Bhattacharya, Sean Spring, Roger McLaughlin, Shin J. Kang, Hans E. Grossniklaus, Demetrios Vavvas, Stephen Monks, John R. MacDougall, Elisabet de los Pinos and John T. Schiller

Mol Cancer Ther February 1 2018 17 (2) 565-574; DOI:10.1158/1535-7163.MCT-17-0953

Models and Technologies

Models and Technologies | AuthorChoice

The Novel Oncolytic Adenoviral Mutant Ad5-3Δ-A20T Retargeted to αvβ6 Integrins Efficiently Eliminates Pancreatic Cancer Cells

Y. K. Stella Man, James A. Davies, Lynda Coughlan, Constantia Pantelidou, Alfonso Blázquez-Moreno, John F. Marshall, Alan L. Parker and Gunnel Halldén

Mol Cancer Ther February 1 2018 17 (2) 575-587; DOI:10.1158/1535-7163.MCT-17-0671

Main menu

User menu

Search

Table of Contents

Highlights

MCT Focus: Developmental Therapeutics in Radiation Oncology

Small Molecule Therapeutics

Cancer Biology and Translational Studies

Large Molecule Therapeutics

Models and Technologies

Issue Highlights

Jump to

Articles

Info for

About MCT